Drug Attached Articles & Analysis
10 news found
By leveraging cutting-edge conjugation methods, targeting drug delivery solutions, and RNAi delivery systems, scientists can gain unprecedented control over the design and synthesis of bioconjugates. ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer. ...
Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. ...
The presentation will highlight Araris’ proprietary linker technology, which enables the conjugation of various potent drug payloads to native “off-the-shelf” antibodies in a single step without the need for further engineering. ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will present data on Araris’ linker technology at the 13th Annual World ADC Conference in San Diego. ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will be presenting at the H.C. Wainwright Preclinical Cancer Drug Discovery: Emerging Targets and Modalities virtual conference on June 29, 2022. ...
The poster presentation highlights the company’s anti-CD79b antibody-drug conjugate (ADC) and the oral presentation, taking place during the conference’s minisymposium, will highlight late-breaking data on a Nectin-4 ADC generated using the company’s proprietary linker technology. ...
The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates using Araris peptide linkers for site-specific bioconjugation,” will be given on March 30, 2022, at 2:15 p.m. ...
OcuRing is a novel drug delivery platform for cataract surgery with potential to eliminate the need for postoperative topical eye drops. $3M DoD award will fund IND-enabling toxicology and manufacturing activities. ...
This foundational patent allows development of ceramics for medical implants with nanosurfacing that enhances cell binding and drug delivery depending on the purpose of implantation. The ceramic nanosurfacing technology dovetails with Nanovis’ technology, offering a range of spinal implant nanosurfaces designed to increase bone to implant growth. ...
ByNanovis